Structure Therapeutics (GPCR) Q2 2026 earnings summary

Executive summary

• Clinical-stage biopharma focused on oral small molecule therapeutics for chronic diseases, leveraging structure-based drug discovery and computational chemistry expertise.

• Lead candidate aleniglipron (oral GLP-1R agonist) advanced to Phase 3 for obesity and related conditions, with robust Phase 2 results supporting progression; first patients dosed in Phase 3 ACCOMPLISH program.

• Pipeline includes amylin receptor agonists (ACCG-2671, ACCG-3535), GIPR/GCGR programs, and LPA1R antagonist for IPF, with multiple ongoing and planned clinical trials.

• Appointment of John Berrios as Chief Commercial Officer, bringing significant commercial expertise in obesity and diabetes.

• No approved products or product revenue to date; operations funded by equity offerings and licensing agreements.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $1,342.7 million as of June 30, 2026.

• Net loss was $182.1 million for the six months ended June 30, 2026, compared to $108.5 million for the same period in 2025.

• Research and development expenses increased 71% year-over-year to $166.6 million for the six months ended June 30, 2026.

• General and administrative expenses rose 42% year-over-year to $41.4 million for the six months ended June 30, 2026.

• Interest and other income increased to $26.3 million for the six months ended June 30, 2026.

Outlook and guidance

• Existing cash and investments expected to fund operations and key clinical milestones through the end of 2028, excluding pre-commercialization manufacturing costs.

• Topline results from ongoing Phase 3 and supplementary trials for aleniglipron expected in late 2026.

• Anticipates continued significant operating losses as R&D and clinical trial investments increase.